Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $455.24M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 2.08M
Average 0.69M
STTK Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Shattuck Labs, Inc.NASDAQ: STTK
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 41.8% from a year ago
Total equity stood at $95.84M at the end of Q1 FY2026, up 41.8% from a year earlier and up 16.3% from the prior quarter. Over 3 fiscal years it compounded at -22.4% a year.
Context
- Total equity amounted to 93.8% of total assets at the end of Q1 FY2026, up 6.3 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +41.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 82.39M USD
- Year-over-year change
- +3.5%
- 4-year CAGR
- -25.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 82.39M | +3.5% |
| FY2024 | 2024-12-31 | 79.63M | -45.0% |
| FY2023 | 2023-12-31 | 144.71M | -17.9% |
| FY2022 | 2022-12-31 | 176.16M | -35.2% |
| FY2021 | 2021-12-31 | 271.79M | — |
Total Equity vs competitors
How STTK compares with its peers on the latest reported figures
- STTK's Mar 2026 total equity of $95.84M is the 7th highest of the 10 companies compared; the peer median is $128.42M.
- Its year-over-year change of +41.8% is the 4th highest of 10, against a peer median of +15.7%.
- Total equity amounts to 93.8% of total assets for STTK, versus a peer median of 82.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $812.66M | +15.7% | +11.8% | 82.0% | |
| Mar 2026 | $183.85M | +5346.9% | +67.8% | 92.3% | |
| Jun 2026 | $172.96M | +533.2% | -43.6% | 91.4% | |
| Sep 2026 | $131.81M | +188.9% | +144.5% | 93.4% | |
| Mar 2026 | $128.42M | +32.2% | +82.0% | 66.6% | |
| Mar 2026 | $104.3M | -26.3% | -1.0% | 78.5% | |
| Mar 2026 | $95.84M | +41.8% | -22.4% | 93.8% | |
NBPNovaBridge Biosciences | Dec 2025 | $33.02M | -97.8% | -77.8% | 88.6% |
| Mar 2026 | $3.89M | -82.6% | -40.5% | 15.8% | |
| Mar 2026 | $1.25M | -55.4% | -49.6% | 57.2% | |
| Peer median (excluding STTK) | $128.42M | +15.7% | -1.0% | 82.0% | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 92.27M | 47.38M | 125.63M | 57.39M | 54.19M |
| Short-term Investments | 176.54M | 113.9M | 5M | 15.6M | 23.87M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 23.3M | 12.6M | 6.23M | 4.41M |
| Total Current Assets | 288.27M | 184.58M | 143.22M | 79.22M | 82.48M |
| Property, Plant & Equipment (Net) | 9.94M | 17.67M | 13.8M | 9.81M | 6.11M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 1M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 381K | 3.07M | 2.54M | 2.02M | 1.44M |
| Total Non-current Assets | 10.32M | 20.74M | 16.34M | 11.83M | 8.55M |
| Total Assets | 298.59M | 205.32M | 159.56M | 91.05M | 91.03M |
| Account Payables | 10.01M | 7.17M | 1.59M | 2.42M | 2.1M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.25M | 5.84M | 4.84M | 2.7M | 3M |
| Total Current Liabilities | 24.59M | 24.97M | 11.45M | 8.92M | 7.05M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.58M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.21M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 2.21M | 4.2M | 3.41M | 2.51M | 1.58M |
| Total Liabilities | 26.8M | 29.17M | 14.86M | 11.42M | 8.64M |
| Common Stock | 5K | 5K | 5K | 5K | 7K |
| Retained Earnings | (117.07M) | (219.01M) | (306.31M) | (381.72M) | (430.53M) |
| Accumulated OCI | (560K) | (877K) | 4K | 2K | 6K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 271.79M | 176.16M | 144.71M | 79.63M | 82.39M |
| Total Debt | 0 | 4.9M | 4.2M | 3.41M | 2.42M |
| Net Debt | (92.27M) | (42.48M) | (121.42M) | (53.98M) | (51.77M) |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.